bioMérieux receives a $ 1 million license fee for access to its markers for blood clotting disorders. bioMérieux to give Gen-Probe an option for the access to bioMérieux NUCLISENS EASYQ® platform. bioMérieux Gains Access to ribosomal RNA markers to support its future growth in molecular biology.
bioMérieux signs New Agreements with Gen-Probe
10 Oktober, 2004
bioMérieux innovates further in the fight against AIDS
27 September, 2004
A major player in the field of in vitro diagnostics, bioMérieux confirms its constant commitment to the fight against AIDS with the launch of two new advanced 4th generation tests for HIV screening. VIDAS® HIV DUO ULTRA and VIDAS HIV DUO QUICK, developed for use on the automated VIDAS immunoanalysis system, are ultra-sensitive tests, providing even earlier detection of HIV infection.
VIDAS® D-Dimer Exclusion™ test from bioMérieux for reliable exclusion of pulmonary embolism and deep vein thrombosis
23 Juli, 2004
bioMérieux announces that its D-dimer assay, VIDAS D-Dimer Exclusion, is now cleared by the U.S. Food and Drug Administration (FDA) to exclude both pulmonary embolism (PE) and deep vein thrombosis (DVT) as a diagnosis in outpatients. VIDAS D-Dimer Exclusion is the first and only D-dimer assay to be cleared for exclusion of both conditions -- with no further testing -- when used in conjunction with a pre-test probability (PTP) assessment, in low-to-moderate probability outpatients.
NucliSens® easyMAG™ – new innovation from bioMérieux for nucleic acid extraction
07 Juni, 2004
A world leader in the field of in vitro diagnostics, bioMérieux announces the launch of its new automated sample preparation platform for the extraction of nucleic acid in molecular diagnostics assays. The NucliSens easyMAG system is the latest innovation in bioMérieux’s range of molecular diagnostic solutions
bioMérieux laboratories grant license to Eppendorf for One Step RT-PCR technology
13 Mai, 2004
Eppendorf AG, Germany, and bioMérieux, France, have concluded a non-exclusive licensing agreement for Eppendorf products using bioMérieux's exclusively controlled One Step RT-PCR technology.
VIDAS® D-Dimer Exclusion test from bioMérieux for reliable exclusion of venous thromboembolism
06 Mai, 2004
bioMérieux announces that following prospective management studies on its VIDAS D-Dimer test resulting in FDA approval and CE marking, the VIDAS D-Dimer New test has been renamed VIDAS D-Dimer Exclusion™. This name change will more accurately reflect the new intended use of the VIDAS D-Dimer Exclusion test, and also reinforce awareness of the significant role D-dimers can play in exclusion strategies for thromboembolic disease.
bioMérieux and South Africa, united in the fight against AIDS
04 Mai, 2004
A major player in the field of infectious disease, bioMérieux, and its exclusive distributor for South Africa, Omnimed, have just won a most important tender for the National Health Laboratory Services of South Africa as regards the fight against the AIDS virus.
BOOM® patent upheld in Europe
20 April, 2004
The European Patent Office’s Board of Appeal has found in favour of bioMérieux in the opposition to its European patent for the Boom technology.
bioMérieux invests in the future of emergency diagnostics
15 April, 2004
A world leader in the field of in vitro diagnostics, with over 40 years experience in infectious diseases, bioMérieux SA recently confirmed its commitment to the field of emergency diagnostics through its presence at the 25th International Symposium on Intensive Care and Emergency Medicine in Brussels on March 21–25, 2005.
NucliSens® miniMAG™, the first product from bioMérieux’s next generation nucleic acid extraction platform now available.
02 April, 2004
bioMérieux announces the introduction of NucliSens miniMAG and NucliSens Magnetic Extraction Reagents, two key components of the company’s next generation nucleic acid extraction technology.